Literature DB >> 20614230

Fenofibrate but not fenofibric acid inhibits 11beta-hydroxysteroid dehydrogenase 1 in C2C12 myotubes.

Chi Hyun Kim1, Ravirala Ramu, Jin Hee Ahn, Myung Ae Bae, Young Sik Cho.   

Abstract

Fibrates and WY-14643 are widely used as lipid-lowering drugs via modulation of peroxisome proliferator-activated receptor alpha (PPAR α) for the treatment of a wide range of metabolic disorders. Here, to address the question whether PPAR α agonists can affect the enzymatic activity of 11beta-hydroxysteroid dehydrogenase1 (11β-HSD1), we tested fibrates and WY-14643 for the inhibition of cellular 11β-HSD1 activity in C2C12 myotubes. Only fenofibrate but not fenofibric acid, an active agonist of PPAR α, exerted a potent inhibitory activity in the cell based assay, showing an IC(50) of 1.6 μM. Furthermore, we also demonstrated that the masking of carboxyl group in fenofibric acid via esterification or amidation was required for the inhibitory potencies of fenofibric acid derivatives against 11β-HSD1. In this presentation, we propose that fenofibrate can display a pharmacodynamic role distinct from fenofibric acid through masking of carboxyl group in fenofibric acid.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20614230     DOI: 10.1007/s11010-010-0532-4

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  23 in total

Review 1.  International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors.

Authors:  Nick Z Lu; Suzanne E Wardell; Kerry L Burnstein; Donald Defranco; Peter J Fuller; Vincent Giguere; Richard B Hochberg; Lorraine McKay; Jack-Michel Renoir; Nancy L Weigel; Elizabeth M Wilson; Donald P McDonnell; John A Cidlowski
Journal:  Pharmacol Rev       Date:  2006-12       Impact factor: 25.468

Review 2.  Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors.

Authors:  B A Hamelin; J Turgeon
Journal:  Trends Pharmacol Sci       Date:  1998-01       Impact factor: 14.819

3.  The biochemical pharmacology of fenofibrate.

Authors:  J Caldwell
Journal:  Cardiology       Date:  1989       Impact factor: 1.869

4.  Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention.

Authors:  Guenther Boden; Carol Homko; Maria Mozzoli; Meijuan Zhang; Karen Kresge; Peter Cheung
Journal:  Diabetes       Date:  2007-01       Impact factor: 9.461

Review 5.  Fibrate therapy in patients with metabolic syndrome and diabetes mellitus.

Authors:  Thomas Dayspring; Gregory Pokrywka
Journal:  Curr Atheroscler Rep       Date:  2006-09       Impact factor: 5.113

Review 6.  Regulation of the peroxisomal beta-oxidation-dependent pathway by peroxisome proliferator-activated receptor alpha and kinases.

Authors:  N Latruffe; M Cherkaoui Malki; V Nicolas-Frances; M C Clemencet; B Jannin; J P Berlot
Journal:  Biochem Pharmacol       Date:  2000-10-15       Impact factor: 5.858

Review 7.  Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in the metabolic syndrome.

Authors:  D N Brindley
Journal:  Int J Obes Relat Metab Disord       Date:  1995-05

8.  Cell-based assay for screening 11beta-hydroxysteroid dehydrogenase 1 inhibitors.

Authors:  Young Sik Cho; Chi Hyun Kim; Hyae Gyeong Cheon
Journal:  Anal Biochem       Date:  2009-06-02       Impact factor: 3.365

9.  Esterase inhibition by grapefruit juice flavonoids leading to a new drug interaction.

Authors:  Ping Li; Patrick S Callery; Liang-Shang Gan; Suresh K Balani
Journal:  Drug Metab Dispos       Date:  2007-04-23       Impact factor: 3.922

10.  A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha ) versus liver X receptor.

Authors:  Jeffrey Thomas; Kelli S Bramlett; Chahrzad Montrose; Patricia Foxworthy; Patrick I Eacho; Denis McCann; Guoqing Cao; Anton Kiefer; Jeff McCowan; Kuo-Long Yu; Timothy Grese; William W Chin; Thomas P Burris; Laura F Michael
Journal:  J Biol Chem       Date:  2002-11-18       Impact factor: 5.157

View more
  4 in total

1.  Virtual screening as a strategy for the identification of xenobiotics disrupting corticosteroid action.

Authors:  Lyubomir G Nashev; Anna Vuorinen; Lukas Praxmarer; Boonrat Chantong; Diego Cereghetti; Rahel Winiger; Daniela Schuster; Alex Odermatt
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

2.  Biopharmaceutical Characterization and Bioavailability Study of a Tetrazole Analog of Clofibric Acid in Rat.

Authors:  Nancy Vara-Gama; Adriana Valladares-Méndez; Gabriel Navarrete-Vazquez; Samuel Estrada-Soto; Luis Manuel Orozco-Castellanos; Julio César Rivera-Leyva
Journal:  Molecules       Date:  2017-02-14       Impact factor: 4.411

3.  Potent and PPARα-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro.

Authors:  Yasser Majeed; Rohit Upadhyay; Sara Alhousseiny; Tarek Taha; Adham Musthak; Yanal Shaheen; Mohtashim Jameel; Chris R Triggle; Hong Ding
Journal:  Sci Rep       Date:  2019-04-19       Impact factor: 4.379

4.  Therapeutic Effects of PPARα Agonist on Ocular Neovascularization in Models Recapitulating Neovascular Age-Related Macular Degeneration.

Authors:  Fangfang Qiu; Greg Matlock; Qian Chen; Kelu Zhou; Yanhong Du; Xiang Wang; Jian-Xing Ma
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-10-01       Impact factor: 4.799

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.